Nature communications · 2025
SON-dependent nuclear speckle rehabilitation alleviates proteinopathies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dion William, Tao Yuren, Chambers Maci, Zhao Shanshan, Arbuckle Riley K, Sun Michelle, Kubra Syeda, Schaich Matthew A, Nie Yuhang, Ye Megan, Jamal Imran, Larsen Mads B, Camarco Daniel, Ickes Eleanor, Wang Haokun H, DuPont C, Wang Bingjie, Liu Silvia, Pi Shaohua, Van Houten Bennett, Chen Bill B, Chen Yuanyuan, Chen Xu, Zhu Bokai
Аннотация
Current treatments targeting individual protein quality control pathways have limited efficacy in alleviating proteinopathies, highlighting the prerequisite for a common druggable target capable of global proteostasis modulation. Building upon our prior research establishing nuclear speckles as pivotal membrane-less organelles for transcriptional control of proteostasis, we aim to alleviate proteinopathies through nuclear speckle rehabilitation. We identify pyrvinium pamoate as a nuclear speckle rehabilitator that enhances protein quality control gene expression and suppresses YAP1 transcriptional activity via decreasing the surface/interfacial tension of nuclear speckle condensates through interaction with the intrinsically disordered region of nuclear speckle scaffold protein SON. In pre-clinical models, nanomolar pyrvinium pamoate protects against retinal degeneration and tauopathy mainly by promoting autophagy and ubiquitin-proteasome activity in a SON-dependent manner without causing stress. Aberrant nuclear speckle morphology, reduced protein quality control and increased YAP1 activity are observed in human tauopathies. Our study provides proof-of-principle of targeting nuclear speckles to ameliorate proteinopathies.